Liraglutide anti-diabetics sanguis saccharo imperium cas no.204656-20-2

Type II diabete

Liraglutide improves imperium sanguinem GLYCOSA. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
Est idoneam ad aegris quorum sanguinem sugar adhuc male regi post maximum tolerari dose of Metformin aut sulfonylureas solum. Non est in coniunctas cum metformin et sulfonylureas.
Actus in GLYCOSA-dependens modo, id est quod erit stimulate insulin secretio solum cum sanguine GLYCOSA campester sunt altior quam normalis, ne "overshoot". Et ideo ostendit negligentia periculo hypoglycemia.
Non habet potentiale ad inhibere apoptosis et stimulating regenerationem Beta cellulis (videatur in animalibus studiis).
Ea decrescit appetitus et inhibits corpus pondus lucrum, ut ostensum est in capite-ad-caput studium versus glimepiride.

Pharmacological actio

Liraglutide est glp-I Analog cum XCVII% sequence homology ad humana glp-I, quod potest ligare et activate in glp-I receptor. Et glp-I receptor est in scopum de patria glp-I, an endogenous incretin hormone quod promovet glucoso concentration-dependens insulin secretio a pancreaticum β cellulis. Dissimilis patria glp-I, pharmacokinentetic et pharmacodynamic profiles Liraglutide in hominibus conveniunt ad semel cotidianum dosing regimen. Post telae iniectio, ejus mechanism of diuturna actio includit: auto-Association, quae retards effusio; binding ad albumin; Superiore enzyme stabilitatem et sic diutius plasma dimidium vitae.

In actione Liraglutide est mediante per suum specifica commercium cum glp-I receptor, unde in augmentum in cyclic adenosine monophosphate (castra). Liraglutide incitans insulin secretionem in GLYCOSA concentration-dependens modo reducendo excess Glucagon secretionem in GLYCOSA concentration-dependens modo.

Itaque cum sanguine GLYCOSA resurgit, insulin secretionem excitetur, dum glucagon secretionem inhibuit. In Contra, Liraglutide reducit insulin secretionem in hypoglycemia absque afficiens glucagon secretionem. Et hypoglycemic mechanism of Liraglutide etiam includit levi prolongationem CARDIACUS exinaniens. Liraglutide reduces corpus pondus corpus adipem massa reducendo fame industria attractio.